Envision Pharma Group
16.1.2024 13:22:25 CET | ACCESS Newswire | Press release
Alice will lead the organization's IMC division made up of experts in medical strategy, medical communications, publications planning and delivery, patient engagement, and more to deliver smarter, faster outcomes for life sciences clients.
HORSHAM, UK / ACCESSWIRE / January 16, 2024 / Envision Pharma Group (Envision) has appointed Alice Choi as President, Integrated Medical Capabilities and Solutions (IMC) and a member of its Executive Leadership Team. In her new role, Alice will lead the organization's IMC division made up of experts in medical strategy, medical communications, publications planning and delivery, patient engagement, and more to deliver smarter, faster outcomes for life sciences clients.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page."I am so pleased to welcome Alice to the Envision team and her invaluable experience as a global life sciences industry leader," shares Howard Miller, CEO of Envision Pharma Group. "Alice brings a depth of strategic expertise, knowledge, and insight in the medical communications, scientific research, and publications field that will be instrumental in propelling our vision forward for our people and serving the needs of our clients."
Alice joins Envision from IPG Health where she most recently served as EVP, Managing Director, Client Solutions, APAC. Prior to this, the bulk of her career was in IPG Health Medical Communications - latterly as Chief Operating Officer for the group and formerly, as Head of Complete Medical Communications. During her tenure, she played a pivotal role in establishing and fulfilling long-term business goals while focusing on building upon key client relationships to foster sustained business growth, development, and operational excellence across several global teams.
Alice is committed to best practices and standards in medical communications, as demonstrated in her current role as Chair of the Healthcare Communications Association and through her success at IPG Health Medical Communications and former tenure as Chair of the International Society of Medical Publications Professionals (ISMPP).
Alice adds, "I have long admired the work done by Envision and am excited to be joining such a stellar team. Medical communications continue to move at a rapid pace, and I look forward to ensuring that we continue leading the field in terms of our people, our quality, and our innovative patient-centric services."
About Envision Pharma Group
Founded in 2001, Envision Pharma Group is a leading global technology-enabled strategic solutions partner for the life sciences industry, working with over 200 pharma and biotech companies, including 19 of the top 20 pharmaceutical companies. Envision supports clients across the product life cycle through a comprehensive suite of services and industry-leading technology solutions that include artificial intelligence and natural language processing, commercialization and integrated strategic consulting, evidence-based scientific communications and engagement, HEOR/market access and data analytics, medical capabilities, and omnichannel solutions. Learn more at www.envisionpharmagroup.com.
Contact Information
Colleen Carter
Associate Director, Communications, Office of CEO
colleen.carter@envisionpharma.com
1 (508) 505 8856
SOURCE: Envision Pharma Group
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
CORRECTION FROM SOURCE: Fermi Announces Binding Lease Agreement with TensorWave11.8.2026 00:40:00 CEST | Press release
Reason for change: Unfinalized version was submitted Intends to grow the partnership to more than 650 megawatts (MW) over three phases First phase to deliver a complete turnkey data center solution with 222 MW beginning in the second half of 2027, representing approximately $6.5 billion in total contracted revenue Fermi and TensorWave have lined up world-class partners to collaborate on the project DALLAS, TX / ACCESS Newswire / August 10, 2026 / Fermi Inc. (NASDAQ:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company"), announced today that it has executed its first binding customer lease at its Project Matador campus in Carson County, Texas. The lease between Fermi's subsidiary Fermi Campus 1 LLC and TensorWave TEX1, LLC, a subsidiary of AI cloud provider TensorWave Inc., covers a facility supported by 222 megawatts (MW) of total facility power following commencement of the final delivery phase. Once fully delivered, the facility is being designed to support tens of t
Fermi Announces Binding Lease Agreement with TensorWave10.8.2026 23:10:00 CEST | Press release
Intends to grow the partnership to more than 650 megawatts (MW) over three phases First phase to deliver a complete turnkey data center solution with 222 MW beginning in the second half of 2027, representing approximately $6.5 billion in total contracted revenue Fermi and TensorWave have lined up world-class partners to collaborate on the project and expect certain of the obligations under the lease to be guaranteed by one of the global leaders in AI DALLAS, TX / ACCESS Newswire / August 10, 2026 / Fermi Inc. (NASDAQ:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company"), announced today that it has executed its first binding customer lease at its Project Matador campus in Carson County, Texas. The lease between Fermi's subsidiary Fermi Campus 1 LLC and TensorWave TEX1, LLC, a subsidiary of AI cloud provider TensorWave Inc., covers a facility supported by 222 megawatts (MW) of total facility power following commencement of the final delivery phase. Once fully delivered
Juno International Corporation Acquires Securities of Rocky Shore Gold Ltd.10.8.2026 23:10:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / August 10, 2026 / Juno International Corporation (formerly Northfield Capital Corporation) (the "Acquiror") announces that it acquired ownership and control of 1,549,000 common shares (the "Subject Shares") of Rocky Shore Gold Ltd. (the "Company") on July 24, 2026 through the facilities of the Canadian Securities Exchange, representing approximately 0.65% of all issued and outstanding common shares of the Company as of such date immediately following such transaction. Immediately before the transaction described above, the Acquiror held an aggregate of 40,569,188 common shares of the Company and common share purchase warrants entitling the Acquiror to acquire an additional 5,180,000 common shares of the Company (the "Warrants"), representing approximately 17.11% of the issued and outstanding common shares of the Company on a non-diluted basis (or approximately 18.88%, on a partially diluted basis, assuming exercise of the Warrants only). Upon completion
Clean Air Metals and Fiore-backed Springbok Ventures Announce Upsize of Non-Brokered Private Placement10.8.2026 20:30:00 CEST | Press release
Not for distribution to United States newswire services or for dissemination in the United States. THUNDER BAY, ON / ACCESS Newswire / August 10, 2026 / Clean Air Metals Inc. ("Clean Air Metals") (TSX.V:AIR)(FRA:CKU)(OTCQB:CLRMF) and Springbok Ventures Inc. ("Springbok") are pleased to announce that, further to the joint news release dated August 1, 2026, due to strong market demand they have agreed to increase the size of the previously announced non-brokered private placement of subscription receipts (the "Offering") to $6.1 million, as follows: 10,000,000 subscription receipts of Springbok (the "Springbok Subscription Receipts") at a price of $0.50 per Springbok Subscription Receipt; and 2,000,000 subscription receipts of Clean Air Metals (the CAM Subscription Receipts") at a price of $0.55 per CAM Subscription Receipt. Each Springbok Subscription Receipt will, subject to satisfaction or waiver of certain escrow release conditions, automatically convert in accordance with its terms
ABL Ascend Advanced Therapies Names Suman Subramanian as Chief Business Officer10.8.2026 10:00:00 CEST | Press release
ROCKVILLE, MD / ACCESS Newswire / August 10, 2026 / ABL Inc and Ascend Advanced Therapies today announced the appointment of Suman Subramanian as Chief Business Officer (CBO), further strengthening the Company's commercial leadership and its commitment to supporting customers with the development and manufacturing of viral vectors, vaccines, biologics and advanced therapies. Suman brings nearly two decades of experience and leadership, supporting emerging biotech and large pharma within the biopharmaceutical industry. He will be responsible for leading the company's global commercial organization, including business development, marketing and strategic partnership functions. As the industry continues to evolve, customers are now increasingly seeking end-to-end CDMO partners capable of translating science and delivering impeccable service whilst reducing technical, operational and manufacturing risks. Through his experience with programs ranging from early-stage development to commercia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom